Skip to Main Content

Paper Details

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.
J Clin Oncol
697
2008
Author NameAffiliation
Gerhardt AttardRoyal Marsden NHS Foundation Trust
  • 1 - 1

Datasets

Release 1.2